Orforglipron
Also known as LY3502970
Orforglipron is an experimental once-daily GLP-1 pill (not an injection) for weight and blood sugar, aiming to deliver GLP-1 benefits in a simple tablet with no food restrictions.
How one dose clears
modeled over ~6 half-lives- Half-life
- 36 h
- Reported range
- 24 h–2.8 days
- Time to peak (Tmax)
- 6.0 h
- Bioavailability
- 79%
- Steady state
- ~7 days
- Typical dose
- 3 mg
Investigational oral, non-peptide (small-molecule) GLP-1 receptor agonist taken once daily — without the food/water restrictions of oral semaglutide.
Mechanism of action
Small-molecule GLP-1 receptor agonist that is orally bioavailable without an absorption enhancer, enhancing glucose-dependent insulin secretion and appetite suppression.
Investigational — not FDA approved. PK from phase 1 studies; once-daily oral dosing.
References
Track Orforglipron for free
Log your doses and PeptideBuddy models Orforglipron's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.